Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)
M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Marcelo C. Pasquini(Cleveland Clinic), Fei‐Fei Liu(Jiangsu Hengrui Medicine (China)), Allison Winter(Cleveland Clinic), Stefan K. Barta(University of Pennsylvania), Brian Hess(Washington University in St. Louis), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Sagar S. Patel(University of Utah), Tamara K. Moyo(Carolinas Medical Center), David Bernasconi(Bristol-Myers Squibb (United States)), Iris Isufi(Yale University), Matthew J. Frigault(Harvard University), Amani Kitali(Bristol-Myers Squibb (United States)), Charalambos Andreadis(University of California, San Francisco), Natalie S. Grover(University of North Carolina at Chapel Hill), Priyanka A. Pophali(University of Wisconsin–Madison), Jennifer L. Crombie(Dana-Farber Cancer Institute), Charimar Santiago Parrilla(Medical College of Wisconsin), Mecide Gharibo(Bristol-Myers Squibb (United States)), Brad Hunter(Intermountain Healthcare), Michael D. Jain(Moffitt Cancer Center)
Cited by 7
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|723
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664